Year None202420232022202120202019 May 14, 2024 Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update May 13, 2024 Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment May 03, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 29, 2024 Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 Apr 10, 2024 Arcutis Appoints David Topper as Chief Financial Officer Apr 05, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 28, 2024 Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference Mar 11, 2024 Arcutis Promotes Todd Tucker to Chief Human Resources Officer Mar 10, 2024 Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last » Displaying 10 - 18 of 34